$3,000 price tag for U.S. hospitals to use effective COVID-19 drug

Local News

Gilead Sciences will charge U.S. hospitals more than $3,000 to use Remdesivir to treat patients with insurance.

The drug maker released its pricing plans Monday, June 29th as it gets ready to begin charging for the drug next month.

The company will charge two prices in the U.S.: one for patients with private insurance, and a lower price for government programs like Medicare.

Remdesivir is the first anti-viral drug shown to be effective in treating COVID-19 patients.

Copyright 2020 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Events Calendar